

GVK Bio to acquire 65% in Aragen Bioscience

fe Bureau

Hyderabad, Jan 29: GVK Bio, a small-molecule contract research organisation (CRO), is acquiring a 65% stake in US-based Aragen Bioscience, Inc, a privately-held pre-clinical CRO specialising in high-value biologics services. Both the companies have signed a strategic agreement for the same. The acquisition will provide GVK Bio with expertise in large molecule research and development services and biological services, apart from customer and technology synergies.

The deal will enable GVK Bio to expand its service offering to a broader base of organisations.

International cooperation/Company.